StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Veracyte's profit margin for the twelve months ending Jun 30, 2026 was 20.4%. For fiscal 2025 it was 12.8%, against 5.4% the year before. The highest annual figure on record is 12.8% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202512.8%+7.4
FY2024Dec 31, 20245.4%+26.0
FY2023Dec 31, 2023-20.6%−8.3
FY2022Dec 31, 2022-12.3%+22.1
FY2021Dec 31, 2021-34.4%−4.7
FY2020Dec 31, 2020-29.7%−19.2
FY2019Dec 31, 2019-10.5%+14.5
FY2018Dec 31, 2018-25.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202617.0%+17.7
Q1 FY2026Mar 31, 202620.6%+14.5
Q4 FY2025Dec 31, 202529.3%+24.9
Q3 FY2025Sep 30, 202514.5%+1.4
Q2 FY2025Jun 30, 2025-0.8%−5.8
Q1 FY2025Mar 31, 20256.2%+8.1
Q4 FY2024Dec 31, 20244.3%+33.1
Q3 FY2024Sep 30, 202413.1%+45.9
Q2 FY2024Jun 30, 20245.0%+14.3
Q1 FY2024Mar 31, 2024-1.9%+7.9
Q4 FY2023Dec 31, 2023-28.8%−24.0
Q3 FY2023Sep 30, 2023-32.9%−21.3
Q2 FY2023Jun 30, 2023-9.3%+3.8
Q1 FY2023Mar 31, 2023-9.8%+11.5
Q4 FY2022Dec 31, 2022-4.8%+10.8
Q3 FY2022Sep 30, 2022-11.5%+11.9
Q2 FY2022Jun 30, 2022-13.1%+3.3
Q1 FY2022Mar 31, 2022-21.3%+92.7
Q4 FY2021Dec 31, 2021-15.6%+7.7
Q3 FY2021Sep 30, 2021-23.4%−10.2
Q2 FY2021Jun 30, 2021-16.4%+36.8
Q1 FY2021Mar 31, 2021-114.1%−76.4
Q4 FY2020Dec 31, 2020-23.3%+1.8
Q3 FY2020Sep 30, 2020-13.3%−10.9
Q2 FY2020Jun 30, 2020-53.3%−45.0
Q1 FY2020Mar 31, 2020-37.6%−31.2
Q4 FY2019Dec 31, 2019-25.1%–
Q3 FY2019Sep 30, 2019-2.4%–
Q2 FY2019Jun 30, 2019-8.3%–
Q1 FY2019Mar 31, 2019-6.5%–

More Veracyte figures

See a number that looks wrong?